Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation
Leiomyosarcoma
0301 basic medicine
Soft tissue sarcoma
Uterine
03 medical and health sciences
PARP inhibitor
0302 clinical medicine
RG1-991
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Case Report
Gynecology and obstetrics
RC254-282
DOI:
10.1016/j.gore.2022.101044
Publication Date:
2022-07-14T13:25:49Z
AUTHORS (5)
ABSTRACT
Uterine leiomyosarcoma (uLMS) is an aggressive mesenchymal tumor associated with a poor prognosis. Research demonstrates that PARP inhibitors (PARPi) improve disease-stable survival in patients with somatic BRCA1/2 mutations through the process of synthetic lethality. Therefore, PARPi’s may have a role in treating gynecologic malignancies with deleterious BRCA1/2 mutations. This patient is a 50-year-old female with a history of stage IB uterine leiomyosarcoma, complicated by recurrence along the vaginal cuff and metastases to the lungs. A somatic BRCA2 mutation was identified, and the patient was started on Olaparib for treatment of recurrent disease. The patient has now been disease free for two years. We recommend next generation sequencing be performed to identify functional BRCA1/2 loss in uLMS as PARPi may be a potential targeted therapy for uLMS.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (15)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....